South Korea · Delayed Price · Currency is KRW DuChemBIO Statistics
Total Valuation
DuChemBIO has a market cap or net worth of KRW 180.20 billion. The enterprise value is 181.92 billion.
| Market Cap | 180.20B |
| Enterprise Value | 181.92B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DuChemBIO has 28.38 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 28.38M |
| Shares Outstanding | 28.38M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 9.35% |
| Owned by Institutions (%) | 0.14% |
| Float | 11.05M |
Valuation Ratios
The trailing PE ratio is 26.48.
| PE Ratio | 26.48 |
| Forward PE | n/a |
| PS Ratio | 4.34 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 5.28 |
| P/FCF Ratio | 15.13 |
| P/OCF Ratio | 14.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.67, with an EV/FCF ratio of 15.27.
| EV / Earnings | 26.65 |
| EV / Sales | 4.38 |
| EV / EBITDA | 10.67 |
| EV / EBIT | 21.83 |
| EV / FCF | 15.27 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.80 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.24 |
| Debt / FCF | 1.74 |
| Interest Coverage | 5.95 |
Financial Efficiency
Return on equity (ROE) is 14.17% and return on invested capital (ROIC) is 14.11%.
| Return on Equity (ROE) | 14.17% |
| Return on Assets (ROA) | 6.98% |
| Return on Invested Capital (ROIC) | 14.11% |
| Return on Capital Employed (ROCE) | 13.61% |
| Weighted Average Cost of Capital (WACC) | 4.74% |
| Revenue Per Employee | 329.44M |
| Profits Per Employee | 54.18M |
| Employee Count | 126 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 18.32 |
Taxes
In the past 12 months, DuChemBIO has paid 344.14 million in taxes.
| Income Tax | 344.14M |
| Effective Tax Rate | 4.80% |
Stock Price Statistics
The stock price has decreased by -37.62% in the last 52 weeks. The beta is 0.06, so DuChemBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -37.62% |
| 50-Day Moving Average | 6,244.40 |
| 200-Day Moving Average | 8,275.35 |
| Relative Strength Index (RSI) | 51.76 |
| Average Volume (20 Days) | 36,487 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DuChemBIO had revenue of KRW 41.51 billion and earned 6.83 billion in profits. Earnings per share was 239.83.
| Revenue | 41.51B |
| Gross Profit | 15.70B |
| Operating Income | 8.07B |
| Pretax Income | 7.17B |
| Net Income | 6.83B |
| EBITDA | 16.80B |
| EBIT | 8.07B |
| Earnings Per Share (EPS) | 239.83 |
Balance Sheet
The company has 19.03 billion in cash and 20.75 billion in debt, with a net cash position of -1.72 billion or -60.56 per share.
| Cash & Cash Equivalents | 19.03B |
| Total Debt | 20.75B |
| Net Cash | -1.72B |
| Net Cash Per Share | -60.56 |
| Equity (Book Value) | 51.57B |
| Book Value Per Share | 1,798.06 |
| Working Capital | 14.70B |
Cash Flow
In the last 12 months, operating cash flow was 12.64 billion and capital expenditures -732.10 million, giving a free cash flow of 11.91 billion.
| Operating Cash Flow | 12.64B |
| Capital Expenditures | -732.10M |
| Depreciation & Amortization | 8.72B |
| Net Borrowing | -6.13B |
| Free Cash Flow | 11.91B |
| FCF Per Share | 419.73 |
Margins
Gross margin is 37.81%, with operating and profit margins of 19.45% and 16.45%.
| Gross Margin | 37.81% |
| Operating Margin | 19.45% |
| Pretax Margin | 17.28% |
| Profit Margin | 16.45% |
| EBITDA Margin | 40.47% |
| EBIT Margin | 19.45% |
| FCF Margin | 28.70% |
Dividends & Yields
DuChemBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | 3.79% |
| FCF Yield | 6.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DuChemBIO has an Altman Z-Score of 7.53 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.53 |
| Piotroski F-Score | 6 |